摘要
替罗非班诱导血小板减少症(tirofiban-induced thrombocytopenia,TIT)通常被认为是一种由药物引发的免疫性血小板减少症,表现为使用替罗非班后血小板快速大幅度减少。随着替罗非班在心脑血管领域的广泛应用,TIT病例报道随之增多,受到医学界关注。本文综述了TIT的研究进展,概述了其临床表现、发病机制、危险因素、诊断及鉴别诊断,并讨论了治疗策略,旨在为临床医生提供更全面的诊治参考,以期优化TIT的管理。
Tirofiban-induced thrombocytopenia(TIT)is a drug-induced immune thrombocytopenia that manifests itself as a significant reduction in platelets after the use of tirofiban.With the increasing use of tirofiban in the cardio-cerebrovascular field,the number of TIT cases is increasing and has received attention from the medical community.This article reviews the research progress of TIT,outlines its clinical manifestations,mechanisms,risk factors,diagnostic methods and differential diagnosis,and focuses on therapeutic strategies.The aim of this article is to provide clinicians with a more comprehensive diagnosis and treatment reference with a view to optimizing the management of TIT.
作者
付娜娜
李文文
FU Nana;LI Wenwen(Department of Neurology,Juye County People's Hospital,Heze,Shandong,274900,China)
出处
《中外医疗》
2024年第27期196-198,共3页
China & Foreign Medical Treatment
